UltraPlex
UltraPlex pioneering sustainable and cost-efficient liposome-based RNA therapeutics delivery.
Status:
Pre-business
SDGs:
Good health and well-being
Industry:
Life science and medical
Impact:
Quality of life
Origin:
Research to Business
School:
School of Science
Established:
2025
The UltraPlex project develops a next-generation liposome-based drug delivery system for RNA therapeutics that is sustainable, cost-efficient, and scalable for pharmaceutical applications. Traditional liposomal formulations face challenges such as high production costs, solvent dependency, material waste, and therapeutic molecule encapsulation inefficiency issues, limiting their commercial viability. UltraPlex addresses these challenges by integrating green chemistry, nanotechnology, and focused ultrasound principles to create an eco-friendly and efficient drug delivery platform.
Contact
Read more about innovation services
News from innovation ecosystem
Teaching and collaborating across Europe: Aalto researchers at TU Darmstadt
Hear from Aalto researchers about their experience at TU Darmstadt.
Recent Advances and Research Trends in AI, Energy & Industry (Online Lecture Series)
Lecture series for doctoral students focusing on artificial intelligence, energy, and Industry 4.0. Register by 31 March.
Startups succeed despite headwinds – revenue of Aalto Startup Center’s high-growth companies increased by 355% in three years
Growth companies emerging from Aalto Startup Center continue to expand strongly despite a challenging economic environment. The combined revenue of the fastest-growing companies increased to EUR 56.95 million in 2024.